Analyst Reco. AtriCure, Inc.

Equities

ATRC

US04963C2098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
23.37 ^USD	+0.86%		+2.91%	-34.52%

Apr. 23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
Apr. 18	AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	Apr. 23	MT
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	Feb. 16	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	Feb. 16	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	Feb. 16	MT
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	Jan. 22	MT
JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	23-10-23	MT
UBS Initiates AtriCure With Buy Rating, Price Target is $56	23-09-29	MT
Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	23-07-26	MT
Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	23-05-03	MT
BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	23-02-22	MT
Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	23-02-22	MT
Canaccord Genuity Adjusts Price Target on AtriCure to $74 From $81, Maintains Buy Rating	23-02-22	MT
Canaccord Genuity Adjusts Price Target on AtriCure to $81 From $67, Maintains Buy Rating	23-02-06	MT
Needham Adjusts Price Target on AtriCure to $58 From $55, Maintains Buy Rating	22-12-19	MT
Canaccord Genuity Adjusts AtriCure Price Target to $65 From $72, Maintains Buy Rating	22-11-02	MT
Needham Adjusts Price Target on AtriCure to $55 From $65, Maintains Buy Rating	22-11-02	MT
BTIG Adjusts Price Target on AtriCure to $71 From $75, Maintains Buy Rating	22-10-17	MT
Needham Adjusts AtriCure's Price Target to $65 From $55, Citing 'Peer Multiple Expansion,' Reiterates Buy Rating	22-08-03	MT
Piper Sandler Adjusts AtriCure's Price Target to $55 From $90, Reiterates Overweight Rating	22-08-03	MT
Stifel Nicolaus Adjusts AtriCure's Price Target to $50 From $70, Reiterates Buy Rating	22-07-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AtriCure, Inc.

Equities

ATRC

US04963C2098

Analyst Reco.

Filters